Neuroprotection of SRT2104 in Murine Ischemia/Reperfusion Injury Through the Enhancement of Sirt1-Mediated Deacetylation

Bai, Xue; Ye, Dan; Shi, Yuxun; Fan, Matthew; Lü, Peng; Feng, Yanlin; Hu, Chenyang; Liao, Jing; Cui, Kai; Tang, Xiujun; Wu, Peiqi; Xu, Fan; Xu, Yue; Huang, Jingjing

doi:10.1167/iovs.64.4.31

Cited by 6 publications

(2 citation statements)

References 82 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, SRT2104 demonstrated a remarkable reduced neuroinflammation after I/R injury. Mechanistic studies further revealed that SRT2104 could effectively reverse the acetylation of p53, NF-κB p65, and Signal Transducer and Activator of Transcription 3 (STAT3) induced by I/R 54 .…”

Section: Srt2104 In Optic Nerve Degenerative Diseasesmentioning

confidence: 99%

Emerging roles of SIRT1 activator, SRT2104, in disease treatment

Chang,

Li,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Silent information regulator 1 (SIRT1) is a NAD+-dependent class III deacetylase that plays important roles in the pathogenesis of numerous diseases, positioning it as a prime candidate for therapeutic intervention. Among its modulators, SRT2104 emerges as the most specific small molecule activator of SIRT1, currently advancing into the clinical translation phase. The primary objective of this review is to evaluate the emerging roles of SRT2104, and to explore its potential as a therapeutic agent in various diseases. In the present review, we systematically summarized the findings from an extensive array of literature sources including the progress of its application in disease treatment and its potential molecular mechanisms by reviewing the literature published in databases such as PubMed, Web of Science, and the World Health Organization International Clinical Trials Registry Platform. We focuses on the strides made in employing SRT2104 for disease treatment, elucidating its potential molecular underpinnings based on preclinical and clinical research data. The findings reveal that SRT2104, as a potent SIRT1 activator, holds considerable therapeutic potential, particularly in modulating metabolic and longevity-related pathways. This review establishes SRT2104 as a leading SIRT1 activator with significant therapeutic promise.

show abstract

Section: Srt2104 In Optic Nerve Degenerative Diseasesmentioning

confidence: 99%

Emerging roles of SIRT1 activator, SRT2104, in disease treatment

Chang,

Li,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Despite the enigmatic behavior of resveratrol, it is currently used in many clinical trials and is generally well tolerated. Therefore, it is possible to get past the preclinical stage of investigation for PD, but likely will require bioengineering improvement ( 187 , 188 ).…”

Section: Senolytic and Senomorphic Secondary Metabolites In ...mentioning

confidence: 99%

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

Miller,

Darji,

Walaieh

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

Drosophila melanogaster is a valuable model organism for a wide range of biological exploration. The well-known advantages of D. melanogaster include its relatively simple biology, the ease with which it is genetically modified, the relatively low financial and time costs associated with their short gestation and life cycles, and the large number of offspring they produce per generation. D. melanogaster has facilitated the discovery of many significant insights into the pathology of Parkinson’s disease (PD) and has served as an excellent preclinical model of PD-related therapeutic discovery. In this review, we provide an overview of the major D. melanogaster models of PD, each of which provide unique insights into PD-relevant pathology and therapeutic targets. These models are discussed in the context of their past, current, and future potential use for studying the utility of secondary metabolites as therapeutic agents in PD. Over the last decade, senolytics have garnered an exponential interest in their ability to mitigate a broad spectrum of diseases, including PD. Therefore, an emphasis is placed on the senolytic and senomorphic properties of secondary metabolites. It is expected that D. melanogaster will continue to be critical in the effort to understand and improve treatment of PD, including their involvement in translational studies focused on secondary metabolites.

show abstract